Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

• Status: Recruiting
• Trial end date: 2025-08-31

Summary

This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6 treatment failed.

• Phase: Phase 2

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Treatments: Gossypol; Gossypol acetic acid